These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36262475)

  • 1. Insights into the binding mode of AS1411 aptamer to nucleolin.
    Bie L; Wang Y; Jiang F; Xiao Z; Zhang L; Wang J
    Front Mol Biosci; 2022; 9():1025313. PubMed ID: 36262475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct investigations of interactions between nucleolins and aptamers on pancreatic cancer and normal cells by atomic force microscopy.
    Li X; Chen L; Kong S; Zhong H; Jiang F; Zhao W
    Ultramicroscopy; 2024 Sep; 263():113986. PubMed ID: 38762964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor targeting with a (99m)Tc-labeled AS1411 aptamer in prostate tumor cells.
    Noaparast Z; Hosseinimehr SJ; Piramoon M; Abedi SM
    J Drug Target; 2015; 23(6):497-505. PubMed ID: 25673264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Surface Nucleolin as a Promising Receptor for Effective AS1411 Aptamer-Mediated Targeted Drug Delivery into Cancer Cells.
    Mosafer J; Mokhtarzadeh A
    Curr Drug Deliv; 2018; 15(9):1323-1329. PubMed ID: 30039760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic studies of anticancer aptamer AS1411 reveal a novel role for nucleolin in regulating Rac1 activation.
    Reyes-Reyes EM; Šalipur FR; Shams M; Forsthoefel MK; Bates PJ
    Mol Oncol; 2015 Aug; 9(7):1392-405. PubMed ID: 25911416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma membrane nucleolin is a receptor for the anticancer aptamer AS1411 in MV4-11 leukemia cells.
    Soundararajan S; Wang L; Sridharan V; Chen W; Courtenay-Luck N; Jones D; Spicer EK; Fernandes DJ
    Mol Pharmacol; 2009 Nov; 76(5):984-91. PubMed ID: 19657047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modified AS1411 Aptamer Suppresses Hepatocellular Carcinoma by Up-Regulating Galectin-14.
    Cho Y; Lee YB; Lee JH; Lee DH; Cho EJ; Yu SJ; Kim YJ; Kim JI; Im JH; Lee JH; Oh EJ; Yoon JH
    PLoS One; 2016; 11(8):e0160822. PubMed ID: 27494117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locking up the AS1411 Aptamer with a Flanking Duplex: Towards an Improved Nucleolin-Targeting.
    Miranda A; Santos T; Largy E; Cruz C
    Pharmaceuticals (Basel); 2021 Feb; 14(2):. PubMed ID: 33557379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism.
    Reyes-Reyes EM; Teng Y; Bates PJ
    Cancer Res; 2010 Nov; 70(21):8617-29. PubMed ID: 20861190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-nucleolin aptamer AS1411: an advancing therapeutic.
    Van den Avont A; Sharma-Walia N
    Front Mol Biosci; 2023; 10():1217769. PubMed ID: 37808518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioactivity of 2'-deoxyinosine-incorporated aptamer AS1411.
    Fan X; Sun L; Wu Y; Zhang L; Yang Z
    Sci Rep; 2016 May; 6():25799. PubMed ID: 27194215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells.
    Soundararajan S; Chen W; Spicer EK; Courtenay-Luck N; Fernandes DJ
    Cancer Res; 2008 Apr; 68(7):2358-65. PubMed ID: 18381443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic applications of AS1411 aptamer, an update review.
    Yazdian-Robati R; Bayat P; Oroojalian F; Zargari M; Ramezani M; Taghdisi SM; Abnous K
    Int J Biol Macromol; 2020 Jul; 155():1420-1431. PubMed ID: 31734366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A nucleolin-targeted multimodal nanoparticle imaging probe for tracking cancer cells using an aptamer.
    Hwang DW; Ko HY; Lee JH; Kang H; Ryu SH; Song IC; Lee DS; Kim S
    J Nucl Med; 2010 Jan; 51(1):98-105. PubMed ID: 20008986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smart AS1411-aptamer conjugated pegylated PAMAM dendrimer for the superior delivery of camptothecin to colon adenocarcinoma in vitro and in vivo.
    Alibolandi M; Taghdisi SM; Ramezani P; Hosseini Shamili F; Farzad SA; Abnous K; Ramezani M
    Int J Pharm; 2017 Mar; 519(1-2):352-364. PubMed ID: 28126548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aptamer-based Targeted Delivery of a G-quadruplex Ligand in Cervical Cancer Cells.
    Carvalho J; Paiva A; Cabral Campello MP; Paulo A; Mergny JL; Salgado GF; Queiroz JA; Cruz C
    Sci Rep; 2019 May; 9(1):7945. PubMed ID: 31138870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, AS1411.
    Sharma VR; Thomas SD; Miller DM; Rezzoug F
    Cancer Invest; 2018; 36(9-10):475-491. PubMed ID: 30396283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AS1411-conjugated gold nanoparticles affect cell proliferation through a mechanism that seems independent of nucleolin.
    Kabirian-Dehkordi S; Chalabi-Dchar M; Mertani HC; Le Guellec D; Verrier B; Diaz JJ; Mehrgardi MA; Bouvet P
    Nanomedicine; 2019 Oct; 21():102060. PubMed ID: 31336175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AS1411 Aptamer Linked to DNA Nanostructures Diverts Its Traffic Inside Cancer Cells and Improves Its Therapeutic Efficacy.
    Vindigni G; Raniolo S; Iacovelli F; Unida V; Stolfi C; Desideri A; Biocca S
    Pharmaceutics; 2021 Oct; 13(10):. PubMed ID: 34683964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-nucleolin Aptamer as a Boom in Rehabilitation of Breast Cancer.
    Janani SK; Dhanabal SP; Sureshkumar R; Nikitha Upadhyayula SS
    Curr Pharm Des; 2022; 28(38):3114-3126. PubMed ID: 36173049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.